Publications by authors named "C Amador-Prous"
Purpose: Our aim was to describe non-AIDS-defining cancer (NADC) mortality among people living with HIV (PLWH), to compare it with that of the general population, and to assess potential risk factors.
Methods: We included antiretroviral-naive PLWH from the multicentre CoRIS cohort (2004-2021). We estimated mortality rates and standardised mortality ratios (SMRs).
Effectiveness of fosfomycin trometamol as oral step-down therapy for bacteraemic urinary tract infections due to MDR Escherichia coli: a post hoc analysis of the FOREST randomized trial.
J Antimicrob Chemother
July 2023
Article Synopsis
- Fosfomycin trometamol is being explored as a potential step-down therapy for patients with bacteraemic urinary tract infections caused by multidrug-resistant E. coli (MDR-Ec), though data is limited.
- In the FOREST trial, patients who transitioned from IV treatments to either oral fosfomycin or other oral medications showed similar clinical and microbiological cure rates, with fosfomycin achieving 78.7% success compared to 80.9% for other drugs.
- However, fosfomycin had a significantly higher relapse rate (15% vs. 4.3%), indicating that while it is a viable option, its effectiveness needs further evaluation due to this concern.
Analysis of urine samples from COVID-19 patients by H NMR reveals important metabolic alterations due to SAR-CoV-2 infection. Previous studies have identified biomarkers in urine that reflect metabolic alterations in COVID-19 patients. We have used H NMR to better define these metabolic alterations since this technique allows us to obtain a broad profile of the metabolites present in urine.
View Article and Find Full Text PDFEffectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections: A Randomized Clinical Trial.
JAMA Netw Open
January 2022
Importance: The consumption of broad-spectrum drugs has increased as a consequence of the spread of multidrug-resistant (MDR) Escherichia coli. Finding alternatives for these infections is critical, for which some neglected drugs may be an option.
Objective: To determine whether fosfomycin is noninferior to ceftriaxone or meropenem in the targeted treatment of bacteremic urinary tract infections (bUTIs) due to MDR E coli.
Article Synopsis
- Chagas disease, caused by the parasite Trypanosoma cruzi, is prevalent in Latin America and poses a global risk due to migration, with many asymptomatic carriers unknowingly infected.
- A study assessed Chagas disease prevalence and knowledge among Latin American migrants in community screenings in Alicante, Spain, during 2016-2018, using blood tests and questionnaires.
- The results showed an 11% prevalence among adults, particularly in Bolivian migrants, with educational efforts linked to better disease knowledge, especially among those receiving information in Spain and having a primary education level.